Cardiac toxicity adverse events include heart failure, pericardial effusion, and decreased left ventricular function. Laboratory abnormalities include elevated CK-MB, cTNT, NT-proBNP, and electrocardiogram abnormalities (QT interval changes).
Conditions
Interventions
No-Cardiotoxicity Group:None
Cardiotoxicity Group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients aged >= 18 years with clinically diagnosed NSCLC; 2.Received Osimertinib monotherapy as maintenance treatment. No other NSCLC therapies, including targeted agents, immunotherapies, or chemotherapy, were administered during the maintenance period.
Exclusion criteria
Exclusion criteria: 1.The patient had pre-existing heart conditions prior to treatment with Osimertinib, including congenital heart disease and acquired heart disease. 2.Clinical data documentation is incomplete.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| CK-MB;cTNT; | — |
Countries
China
Contacts
Public ContactZiye Zhou
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed